Kuur Therapeutics cancer cell therapies

Kuur Therapeutics is a specialized biotechnology brand focused on the development of off-the-shelf engineered CAR-NKT cell therapies for cancer treatment. Originally founded as Cell Medica, the brand evolved into Kuur Therapeutics in 2019 to focus specifically on its innovative natural killer T cells (NKT cells) platform, which aims to provide more effective treatments for both solid tumors and hematological malignancies.

The brand has undergone significant corporate shifts over the years. In May 2021, Kuur Therapeutics was acquired by Athenex, Inc., a global biopharmaceutical company. Following corporate restructuring within the biotech sector through 2024 and 2025, the brand's assets and intellectual property have transitioned under specialized oncology-focused pharmaceutical management to continue clinical trials and research. The primary research and development activities take place in the United States, specifically in Houston, Texas, often in collaboration with leading academic institutions like Baylor College of Medicine.